Article
Ophthalmology
Carlos Pavesio, Carsten Heinz
Summary: The study findings suggest that in patients with bilateral non-infectious uveitis of the posterior segment (NIU-PS), the use of 0.2 µg/day fluocinolone acetonide implant (FAi) can effectively reduce recurrence rates, decrease the need for adjunctive medications, and improve visual acuity over a 36-month period.
Article
Pharmacology & Pharmacy
Lucy Joanne Kessler, Grzegorz Labuz, Gerd U. Auffarth, Ramin Khoramnia
Summary: This study aimed to predict the need for additional local corticosteroids in patients receiving ophthalmic implants, and identified some potential predictors, including the number of corticosteroids the patient received previously, changes in choroidal vascularity index, etc.
Article
Ophthalmology
Michael A. Singer, Veeral Sheth, Sam E. Mansour, Brandon Coughlin, Victor H. Gonzalez
Summary: The study demonstrates that the 0.19-mg fluocinolone acetonide intravitreal implant has good efficacy and safety in patients with diabetic macular edema, improving visual outcomes and reducing treatment burden compared to previous therapies.
Article
Medicine, General & Internal
Alessandro Arrigo, Emanuela Aragona, Luigi Capone, Carlo Di Biase, Rosangela Lattanzio, Francesco Bandello
Summary: The study identified quantitative IOP cutoffs associated with the onset of FAc-related IOP increases, showing that a certain percentage increase in IOP after DEX implant is significantly associated with the need for IOP-lowering medications or surgery after FAc implant. Different IOP changes in different groups can help predict the necessity of IOP-lowering treatments.
FRONTIERS IN MEDICINE
(2021)
Article
Ophthalmology
Sarah Lebrize, Louis Arnould, Abderrahmane Bourredjem, Catharina Busch, Matus Rehak, Pascale Massin, Joao Barbosa-Breda, Marco Lupidi, Cesare Mariotti, Mahmoud Hamza, Alice Grise-Dulac, Pierre-Henry Gabrielle, Stephanie Baillif, Catherine Creuzot-Garcher
Summary: The aim of this study was to assess the impact of FAc intravitreal implant on intraocular pressure (IOP). The results showed that FAc implant led to a substantial elevation in IOP, which required monitoring and treatment with IOP-lowering medication.
OPHTHALMOLOGY AND THERAPY
(2022)
Article
Medicine, General & Internal
Muaas Hikal, Nil Celik, Gerd Uwe Auffarth, Lucy Joanne Kessler, Christian Steffen Mayer, Ramin Khoramnia
Summary: The study evaluated the efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant in the treatment of non-infectious uveitic macular edema, showing resolution of macular edema in most cases, along with improvements in visual acuity and central retinal thickness.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Lara Buhl, Stephan Thurau, Christoph Kern
Summary: Through a retrospective cohort study, we found that the 0.19-mg fluocinolone acetonide implant showed effectiveness in treating noninfectious uveitis in standard clinical practice. Additionally, administering high-dose corticosteroids before FAi can benefit patients with increased baseline uveitis activity.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Hamidah Mahmud, Tessnim R. Ahmad, John A. Gonzales, Jay M. Stewart
Summary: This retrospective study evaluated the efficacy of the fluocinolone acetonide intravitreal implant as monotherapy for uveitis. The results suggested that while the implant may not be sufficient as a sole treatment, it could be effective as an adjunctive therapy.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Pharmacology & Pharmacy
Stephanie Baillif, Pascal Staccini, Michel Weber, Marie-Noelle Delyfer, Yannick Le Mer, Vincent Gualino, Laurence Collot, Pierre-Yves Merite, Catherine Creuzot-Garcher, Laurent Kodjikian, Pascale Massin
Summary: In this multicenter retrospective observational study, switching from dexamethasone implant to fluocinolone acetonide implant was found to be effective and safe in treating diabetic macular edema eyes. A short time between the switch was associated with reduced central macular thickness fluctuations and the need for early additional treatments.
Article
Pharmacology & Pharmacy
Thibaud Mathis, Maxence Papegaey, Cecile Ricard, Amina Rezkallah, Frederic Matonti, Aditya Sudhalkar, Cristina Vartin, Corinne Dot, Laurent Kodjikian
Summary: In this study, the functional and anatomical efficacy of the fluocinolone acetonide (FAc) implant in treating chronic diabetic macular edema (DME) was evaluated. The results showed that the FAc implant was effective and safe in patients with chronic DME who had previously received other treatments.
Article
Ophthalmology
Hans Andrews, Archana Nair, Saif Hamdan, Sapna Gangaputra, Stephen J. Kim
Summary: This retrospective case series evaluated the therapeutic efficacy and safety of the long-acting fluocinolone acetonide 0.18-mg injectable intravitreal implant (FAi) in chronic uveitis. The results showed that FAi was beneficial in controlling intraocular inflammation and improving macular edema, especially when used in conjunction with systemic immunosuppression. The incidence of steroid-induced increase in intraocular pressure and cataract surgery in this study was consistent with prior clinical trials and published literature.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2023)
Review
Ophthalmology
Abdus Samad Ansari, Zain Amir, Gwyn S. Williams
Summary: Treatment of JIA-associated uveitis often requires long-term corticosteroids or immunosuppressive agents. In complex cases, the 0.19 mg fluocinolone acetonide implant may provide a safe and effective alternative for prolonged intravitreal administration.
OPHTHALMOLOGY AND THERAPY
(2021)
Article
Ophthalmology
Ramin Khoramnia, Tunde Peto, Frank Koch, Simon R. Taylor, Joao Paulo Castro de Sousa, Lauren Hill, Clare Bailey, Usha Chakravarthy
Summary: The ILUVIEN Registry Safety Study evaluated the safety and effectiveness of the fluocinolone acetonide (FAc) implant in real-world practices in Europe. The study showed that the FAc implant has a favorable and long-term benefit-to-risk profile in eyes with chronic diabetic macular edema, with additional benefits observed when used earlier in the disease.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2023)
Article
Ophthalmology
S. Pockar, I Leal, R. Chhabra, Np Jones, Lr Steeples
Summary: This retrospective observational study evaluated the efficacy and safety of 0.19 mg fluocinolone acetonide insert (FAi) in the treatment of chronic noninfectious uveitis (NIU). The results showed that FAi effectively improved the condition and maintained stable visual acuity.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Ophthalmology
Freia McGregor, Andrew D. Dick, Tomas Burke
Summary: This case report demonstrates the effectiveness of a newly licensed treatment in achieving quiescence in refractory anterior uveitis causing cystoid macular oedema, even in the presence of an acute relapse.
CASE REPORTS IN OPHTHALMOLOGY
(2021)
Review
Ophthalmology
Nidhi Relhan, Thomas A. Albini, Avinash Pathengay, Ajay E. Kuriyan, Darlene Miller, Harry W. Flynn
BRITISH JOURNAL OF OPHTHALMOLOGY
(2016)
Article
Ophthalmology
Steven Gayer, Howard D. Palte, Thomas A. Albini, Harry W. Flynn, Ricardo Martinez-Ruiz, Nelson Salas, Andrew J. Mcclellan, Nidhi Relhan, Jean-Marie Parel
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2016)
Article
Ophthalmology
Milan Shah, Nidhi Relhan, Ajay E. Kuriyan, Janet L. Davis, Thomas A. Albini, Avinash Pathengay, Darlene Miller, Harry W. Flynn
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2016)
Article
Ophthalmology
D. Wilkin Parke, David R. P. Almeida, Thomas A. Albini, Camila V. Ventura, Audina M. Berrocal, Robert A. Mittra
Article
Ophthalmology
Marcela Marsiglia, Roberto Gallego-Pinazo, Eduardo Cunha de Souza, Marion R. Munk, Suquin Yu, Sarah Mrejen, Emmett T. Cunningham, Brandon J. Lujan, Naomi R. Goldberg, Thomas A. Albini, Alain Gaudric, Catherine Francais, Richard B. Rosen, K. Bailey Freund, Lee M. Jampol, Lawrence A. Yannuzzi
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2016)
Article
Ophthalmology
Francesco Pichi, Sunil K. Srvivastava, Saradha Chexal, Andrea Lembo, Luiz H. Lima, Piergiorgio Neri, Andrea Saitta, Jay Chhablani, Thomas A. Albini, Paolo Nucci, K. Bailey Freund, Hyewon Chung, Careen Y. Lowder, David Sarraf
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2016)
Editorial Material
Ophthalmology
Camila V. Ventura, Thomas A. Albini, Audina M. Berrocal
JAMA OPHTHALMOLOGY
(2016)
Article
Ophthalmology
Ella H. Leung, Harry W. Flynn, Thomas A. Albini, Carlos A. Medina
OPHTHALMIC SURGERY LASERS & IMAGING RETINA
(2016)
Article
Ophthalmology
Samuel P. Burke, Howard F. Fine, Thomas A. Albini
OPHTHALMIC SURGERY LASERS & IMAGING RETINA
(2016)
Article
Ophthalmology
Carlos A. Medina, Michelle R. Butler, Avnish A. Deobhakta, Michael R. Banitt, Thomas A. Albini, William E. Smiddy, Audina M. Berrocal, Steven J. Gedde, Harry W. Flynn
OPHTHALMIC SURGERY LASERS & IMAGING RETINA
(2016)
Article
Medicine, General & Internal
Ajay E. Kuriyan, Thomas A. Albini, Justin H. Townsend, Marianeli Rodriguez, Hemang K. Pandya, Robert E. Leonard, M. Brandon Parrott, Philip J. Rosenfeld, Harry W. Flynn, Jeffrey L. Goldberg
NEW ENGLAND JOURNAL OF MEDICINE
(2017)
Review
Ophthalmology
Francesco Pichi, David Sarraf, Sruthi Arepalli, Careen Y. Lowder, Emmett T. Cunningham, Piergiorgio Neri, Thomas A. Albini, Vishali Gupta, Kimberly Baynes, Sunil K. Srivastava
PROGRESS IN RETINAL AND EYE RESEARCH
(2017)
Article
Ophthalmology
Allen C. Ho, Thomas A. Albini, David M. Brown, David S. Boyer, Carl D. Regillo, Jeffrey S. Heier
JAMA OPHTHALMOLOGY
(2017)
Letter
Ophthalmology
Steven Gayer, Howard D. Palte, Thomas A. Albini, Harry W. Flynn, Ricardo Martinez-Ruiz, Nelson Salas, Andrew J. Mcclellan, Nidhi Relhan, Jean-Marie Parel
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2017)
Article
Ophthalmology
Nicolas A. Yannuzzi, Nancy Si, Nidhi Relhan, Ajay E. Kuriyan, Thomas A. Albini, Audina M. Berrocal, Janet L. Davis, William E. Smiddy, Justin Townsend, Darlene Miller, Harry W. Flynn
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2017)